About Farapulse
Farapulse is a Healthcare company based in Menlo Park (United States) founded in 2014. Devices for cardiac ablation via pulsed field technology are developed. Farapulse has raised $36.3 million across 6 funding rounds from investors including Boston Scientific, European Union and F-Prime Capital. Its website farapulse.com draws about 12 thousand monthly visits. Farapulse offers products and services including FARAPULSE PFA System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is Boston Scientific Corporation. Its competitors include Adagio Medical, Affera and Field Medical; 2 of its 3 listed competitors have raised funding.
Company details
Farapulse was founded in 2014 and is based in Menlo Park, United States. Operations focus on the medical device sector, specifically cardiac ablation using pulsed field ablation techniques. The flagship product, ENDO FARAWAVE, consists of a percutaneous catheter designed to produce transmural and contiguous lesions on the endocardium. Another device, EPI FARAONE, is intended for creating lesions around pulmonary veins.
- Headquarters Menlo Park, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website farapulse.com/us/en/home.html
- Social LinkedIn X
- Legal Name Boston Scientific Corporation
- Total Equity Funding$36.3M (USD)
in 6 rounds
- Latest Funding Round$2.14M (USD), Grant
Mar 2021
- InvestorsBoston Scientific
& 2 more
Products & Services of Farapulse
Farapulse offers a comprehensive portfolio of products and services, including FARAPULSE PFA System.
Uses electrical pulses to treat atrial fibrillation by isolating pulmonary veins safely.
Funding Insights of Farapulse
Farapulse has successfully raised a total of $36.3M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.14 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $36.3M
- Total Rounds 6
- Last Round Grant — $2.14M
- First Round $4.3M
(Oct 2015)
- Investors Count 3
All 6 funding rounds of Farapulse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $2.14M | Grant | – | – | |
| Sep 2020 | Series C | – | Boston Scientific | – | |
| May 2018 | $12M | Series B | – | – | – |
| Jul 2017 | $5M | Series A | – | – | – |
| Mar 2016 | $15M | Series A | – | – | – |
| Oct 2015 | $4.3M | Seed | – | F-Prime Capital | – |
3 investors in total: 3 institutional.
Investors in Farapulse
Farapulse has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, European Union and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Farapulse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Farapulse
5 people are tracked at Farapulse (2 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Shruthi Chandran | Sr. Director, Quality Assurance | Leadership |
Kit Schneider | Sr. Director of Clinical and Preclinical Engineering | Leadership |
Joan Simon | Project Manager | Team |
Anjali Gupta | Principal Quality Engineer | Team |
Maggie R. | Principal Finance Lead | Team |
Complete people profiles for Farapulse
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Farapulse
3 dated milestones of Farapulse across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Farapulse is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Grant, of $2.1M.
Competitors of Farapulse
Farapulse has 3 listed competitors in our database, 2 of them funded. They include Adagio Medical, Affera and Field Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adagiomedical.com | 2011 | Laguna Hills, United States | $72.14M | 72 | Cardiovascular therapies are developed by Adagio Medical in stealth mode. | |
| affera.com | 2014 | Boston, United States | 30 | Devices for treating heart rhythm disorders are developed. | ||
| fieldmedicalinc.com | 2022 | Encinitas, United States | $75M | Pulsed electric field ablation devices for heart arrhythmias are developed. |
Detailed competitors of Farapulse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Farapulse
The website of Farapulse (farapulse.com) receives about 12.4K visits a month.
- Monthly visits12.4K
▼ 25% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Farapulse (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Farapulse
Complete news archive for Farapulse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Farapulse
Farapulse was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Farapulse is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Farapulse is a funded company, having raised a total of $36.3M across 6 funding rounds to date. The company's 1st funding round was a Seed of $4.3M, raised on Oct 2015.
Farapulse was founded in 2014 and is based in Menlo Park, United States. Operations focus on the medical device sector, specifically cardiac ablation using pulsed field ablation techniques. The flagship product, ENDO FARAWAVE, consists of a percutaneous catheter designed to produce transmural and contiguous lesions on the endocardium. Another device, EPI FARAONE, is intended for creating lesions around pulmonary veins.
Farapulse's top competitors include Adagio Medical, Field Medical and Affera.
Farapulse offers FARAPULSE PFA System.
Farapulse has 3 investors. Key investors include Boston Scientific, European Union, and F-Prime Capital.
Farapulse operates through Boston Scientific Corporation.